jkd The Journal of Korean Diabetes J Korean Diabetes 2233-7431 2714-0547 Korean Diabetes Association 10.4093/jkd.2014.15.3.146 jkd-15-146 Focused Issue Glucose Lowering Effect of SGLT2 Inhibitors: A Review of Clinical Studies KimHae Jin Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea 교신저자: 김혜진, 경기도 수원시 영통구 월드컵로 206 아주대학교병원 내분비대사내과, E-mail: jinkim@ajou.ac.kr 12014 712014 153 146150 Copyright © 2014 Korean Diabetes Association 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract

There are numerous glucose lowering agents in clinical use for type 2 diabetic patients, yet most do not achieve glycemic targets. Recently, inhibitors of the sodium glucose cotransporter 2 (SGLT2) have been developed, which show great potential of being a novel therapeutic option to treat type 2 diabetes. Many researches have turned their attention to the kidney as a target because renal glucose reabsorption is increased in type 2 DM. SGLT2 is a protein transporter that mediates glucose reabsorption from glomerular filtrates. In an insulin-independent manner, inhibition of SGLT2 increases urinary glucose excretion and decreases plasma glucose levels. To date, there are a few SGLT2 inhibiting agents being clinically studied both as a monotherapy and in combination with other antidiabetic agents. This review will focus on the efficacy of SGLT2 inhibitors based on clinical studies.

 Hypoglycemic agents Sodium glucose cotransporter 2 Type 2 diabetes mellitus REFERENCES Gerich JE Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications Diabet Med 20102713642 Hasan FM Alsahli M Gerich JE SGLT2 inhibitors in the treatment of type 2 diabetes Diabetes Res Clin Pract 2014104297322 Fujita Y Inagaki N Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action J Diabetes Investig 2014526575 Kaku K Inoue S Matsuoka O Kiyosue A Azuma H Hayashi N Tokudome T Langkilde AM Parikh S Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial Diabetes Obes Metab 20131543240 List JF Woo V Morales E Tang W Fiedorek FT Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes Diabetes Care 2009326507 Ferrannini E Ramos SJ Salsali A Tang W List JF Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial Diabetes Care 201033221724 Ji L Ma J Li H Mansfield TA T'joen CL Iqbal N Ptaszynska A List JF Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study Clin Ther 20143684100.e9 Henry RR Murray AV Marmolejo MH Hennicken D Ptaszynska A List JF Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial Int J Clin Pract 20126644656 Bailey CJ Gross JL Pieters A Bastien A List JF Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial Lancet 2010375222333 Bolinder J Ljunggren Ö Kullberg J Johansson L Wilding J Langkilde AM Sugg J Parikh S Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin J Clin Endocrinol Metab 201297102031 Nauck MA Del Prato S Meier JJ Durán-García S Rohwedder K Elze M Parikh SJ Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care 201134201522 del Prato S Nauck MA Durán-garcia S Rohwedder K Theuerkauf A Langkilde AM Parikh SJ Durability of dapagliflozin vs glipizide as add-on therapies in T2DM inadequately controlled on metformin: 4-year data. In: American Diabetes Association. 73rd Scientific Session 2013 Jun Chicago. Strojek K Yoon KH Hruba V Elze M Langkilde AM Parikh S Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial Diabetes Obes Metab 20111392838 Rosenstock J Vico M Wei L Salsali A List JF Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy Diabetes Care 20123514738 Jabbour SA Hardy E Sugg J Parikh S Study 10 Group Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study Diabetes Care 20143774050 Wilding JP Norwood P T'joen C Bastien A List JF Fiedorek FT A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment Diabetes Care 200932165662 Kohan DE Fioretto P Tang W List JF Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control Kidney Int 20148596271 Stenlöf K Cefalu WT Kim KA Alba M Usiskin K Tong C Canovatchel W Meininger G Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise Diabetes Obes Metab 20131537282 Inagaki N Kondo K Yoshinari T Maruyama N Susuta Y Kuki H Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study Diabetes Obes Metab 201315113645 Lavalle-González FJ Januszewicz A Davidson J Tong C Qiu R Canovatchel W Meininger G Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial Diabetologia 201356258292 Matthews D Fulcher G Perkovic V de Zeeuw D Mahaffey KW Rosenstock J Davies M Capuano G Desai M Shaw W Vercruysse F Meininger G Neal B Efficacy and safety of canagliflozin, an inhibitor of sodium glucose cotransporter 2, added on to insulin therapy with or without oral agents in type 2 diabetes Diabetologie und Stoffwechsel 20138Suppl 1S251 Schernthaner G Gross JL Rosenstock J Guarisco M Fu M Yee J Kawaguchi M Canovatchel W Meininger G Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial Diabetes Care 201336250815 Forst T Guthrie R Goldenberg R Yee J Vijapurkar U Meininger G Stein P Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone Diabetes Obes Metab 20141646777 Ferrannini E Seman L Seewaldt-Becker E Hantel S Pinnetti S Woerle HJ A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes Diabetes Obes Metab 2013157218 Rosenstock J Seman LJ Jelaska A Hantel S Pinnetti S Hach T Woerle HJ Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia Diabetes Obes Metab 201315115460 Ferrannini E Berk A Hantel S Pinnetti S Hach T Woerle HJ Broedl UC Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes Diabetes Care 201336401521 Häring HU Merker L Seewaldt-Becker E Weimer M Meinicke T Woerle HJ Broedl UC EMPA-REG METSU Trial Investigators Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial Diabetes Care 2013363396404 Rosenstock J Jelaska A Frappin G Salsali A Kim G Woerle HJ Broedl UC EMPA-REG MDI Trial Investigators Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes Diabetes Care 201437181523 Kovacs CS Seshiah V Swallow R Jones R Rattunde H Woerle HJ Broedl UC EMPA-REG PIO™ trial investigators Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial Diabetes Obes Metab 20141614758 Fonseca VA Ferrannini E Wilding JP Wilpshaar W Dhanjal P Ball G Klasen S Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus J Diabetes Complications 20132726873 Kashiwagi A Kazuta K Goto K Yoshida S Ueyama E Utsuno A Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study Diabetes Obes Metab 2014 Jun 12 [Epub]. http://dx.doi.org/10.1111/dom.12331 Seino Y Sasaki T Fukatsu A Ubukata M Sasaki T Kasai Y Sakai S Samukawa Y Luseogliflozin, a SGLT2 inhibitor, improves glycaemic control and reduces body weight as monotherapy up to 52 weeks in Japanese patients with type 2 diabetes mellitus Diabetologia 201356Suppl 1S384 Inagaki N Seino Y Sasaki T Fukatsu A Ubukata M Umeuchi H Sakai S Samukawa Y Luseogliflozin, a selective SGLT2 inhibitor, added on to glimepiride for 52 weeks improves glycaemic control with no major hypoglycaemia in Japanese type 2 diabetes patients Diabetologia 201356Suppl 1S82 Haneda M Seino Y Sasaki T Fukatsu A Ubukata M Sato Y Sakai S Samukawa Y Luseogliflozin, a SGLT2 inhibitor, as add-on therapy to 5 types of oral antidiabetic drugs improves glycaemic control and reduces body weight in Japanese patients with type 2 diabetes mellitus Diabetologia 201356Suppl 1S384 Tanizawa Y Araki E Tobe K Terauchi Y Utsunomiya K Iwamoto Y Watada H Kaku K the Tofogliflozin 004 and 005 Study group Efficacy and safety of tofogliflozin administered for 52 weeks as monotherapy or combined with other oral hypoglycaemic agents in Japanese patients with type 2 diabetes Diabetologia 2013 56Suppl 1S82S83 Zambrowicz B Ding ZM Ogbaa I Frazier K Banks P Turnage A Freiman J Smith M Ruff D Sands A Powell D Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes Clin Ther 201335273285.e7 S Figures

Changes in glycated hemoglobin (HbA1C) in trials with sodium glucose cotransporter 2 inhibitors. PBO, placebo. Adapted from Fujita Y et al. J Diabetes Investig. 2014;5:265-75[3].